可溶性B7-H4分子在乳腺癌患者血清中的表达及其临床意义

目的 探讨乳腺癌患者血清中可溶性B7-H4分子（sB7-H4）的表达及临床意义。方法 采用ELISA法检测70例乳腺癌患者、41例良性乳腺疾病患者及28例健康女性血清中sB7-H4的含量，并分析乳腺癌患者血清中sB7-H4含量与临床病理特征的关系；同时采用PCR及免疫组织化学法分别检测B7-H4 mRNA及蛋白在乳腺癌及癌旁组织中的表达。结果 乳腺癌患者血清中sB7-H4含量的中位值为26.54μg/ml，显著高于良性乳腺疾病组的5.69μg/ml（U=844.0，P＜0.01）及健康对照组的15.71μg/ml（U=727.0，P＜0.05）。乳腺癌患者血清中sB7-H4含量与淋巴结转移显著相关（χ2=6.944，P＜0.01），而与其他临床病理特征无关。乳腺癌及癌旁组织中均可检测到B7-H4 mRNA及蛋白的表达。结论 sB7-H4含量在乳腺癌患者血清中显著增加，并与淋巴结转移有关，可作为乳腺癌诊断与治疗的潜在血清标志物。

Expression of soluble B7-H4 molecule in sera from breast cancer patients and its clinical implications

Objective To investigate the serum soluble B7-H4（sB7-H4） level in breast cancer patients and its clinical implications.Methods The sB7-H4 levels in sera from 70 cases of breast cancer patients,41 cases of benign breast disease patients and 28 cases of healthy female donors were detected by ELISA.Clinical implications were also analyzed.B7-H4 mRNA and protein expression in both breast cancer and adjacent normal tissues was detected by PCR and immunohistochemistry methods,respectively.Results The median sB7-H4 level in sera of breast cancer patients was 26.54μg/ml,significantly higher than 5.69μg/ml of benign breast disease patients（U=844.0,P〈0.01）,as well as 15.71μg/ml in healthy donors（U=727.0,P〈0.05）.The sB7-H4 level in sera from breast cancer patients was positively correlated to lymph nodal metastasis status（χ2=6.944,P〈0.01）,while it was not correlated to any other clinicopathological parameters.We also verified that both mRNA and protein expression of B7-H4 could be detected in breast cancer tissues as well as adjacent normal tissues,respectively.Conclusion The increased sB7-H4 level in sera from breast cancer patients is significantly correlated to nodal metastasis status,which suggests that the sB7-H4 level may be developed as a candidate serum marker for breast cancer diagnosis.